Home > News > pSivida cancer cure ready for human testing
April 6th, 2004
pSivida cancer cure ready for human testing
Abstract:
pSivida Limited (PSD) today announced that its Singaporean subsidiary, pSiOncology Pte Ltd has successfully completed a final pre-clinical study for its lead BioSiliconTM product, BrachySilTM. This important and final pre-clinical milestone now paves the way for a ‘first in man’ evaluation of both BioSilicon and BrachySil, they announced. BrachySil is the Company’s lead product and is targeted to the substantial brachytherapy market, which is currently worth $600 million and expected to exceed US$1 billion by 2005.
Source:
egoli
Bookmark:
| Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||